Multifactorial ERβ and NOTCH1 control of squamous differentiation and cancer by Brooks, Yang Sui et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2014
Multifactorial ER￿ and NOTCH1 control of squamous differentiation and
cancer
Brooks, Yang Sui; Ostano, Paola; Jo, Seung-Hee; Dai, Jun; Getsios, Spiro; Dziunycz, Piotr; Hofbauer,
Günther F L; Cerveny, Kara; Chiorino, Giovanna; Lefort, Karine; Dotto, G Paolo
Abstract: Downmodulation or loss-of-function mutations of the gene encoding NOTCH1 are associated
with dysfunctional squamous cell differentiation and development of squamous cell carcinoma (SCC) in
skin and internal organs. While NOTCH1 receptor activation has been well characterized, little is known
about how NOTCH1 gene transcription is regulated. Using bioinformatics and functional screening
approaches, we identified several regulators of the NOTCH1 gene in keratinocytes, with the transcription
factors DLX5 and EGR3 and estrogen receptor ￿ (ER￿) directly controlling its expression in differentiation.
DLX5 and ERG3 are required for RNA polymerase II (PolII) recruitment to the NOTCH1 locus, while
ER￿ controls NOTCH1 transcription through RNA PolII pause release. Expression of several identified
NOTCH1 regulators, including ER￿, is frequently compromised in skin, head and neck, and lung SCCs
and SCC-derived cell lines. Furthermore, a keratinocyte ER￿-dependent program of gene expression is
subverted in SCCs from various body sites, and there are consistent differences in mutation and gene-
expression signatures of head and neck and lung SCCs in female versus male patients. Experimentally
increased ER￿ expression or treatment with ER￿ agonists inhibited proliferation of SCC cells and promoted
NOTCH1 expression and squamous differentiation both in vitro and in mouse xenotransplants. Our data
identify a link between transcriptional control of NOTCH1 expression and the estrogen response in
keratinocytes, with implications for differentiation therapy of squamous cancer.
DOI: 10.1172/JCI72718
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-108889
Published Version
Originally published at:
Brooks, Yang Sui; Ostano, Paola; Jo, Seung-Hee; Dai, Jun; Getsios, Spiro; Dziunycz, Piotr; Hofbauer,
Günther F L; Cerveny, Kara; Chiorino, Giovanna; Lefort, Karine; Dotto, G Paolo (2014). Multifactorial
ER￿ and NOTCH1 control of squamous differentiation and cancer. Journal of Clinical Investigation,
124(5):2260-2276. DOI: 10.1172/JCI72718
Research article
2260 The Journal of Clinical Investigation   http://www.jci.org   Volume 124   Number 5   May 2014
Multifactorial ERβ and NOTCH1 control of 
squamous differentiation and cancer
Yang Sui Brooks,1,2 Paola Ostano,3 Seung-Hee Jo,1,2 Jun Dai,1,2 Spiro Getsios,4 Piotr Dziunycz,5  
Günther F.L. Hofbauer,5 Kara Cerveny,6 Giovanna Chiorino,3 Karine Lefort,7,8 and G. Paolo Dotto1,7
1Cutaneous Biology Research Center, Massachusetts General Hospital, Boston, Massachusetts, USA. 2Department of Dermatology, Harvard Medical School, 
Boston, Massachusetts, USA. 3Cancer Genomics Laboratory, Edo and Elvo Tempia Valenta Foundation, Biella, Italy. 4Department of Dermatology,  
Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. 5Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.  
6Department of Biology, Reed College, Portland, Oregon, USA. 7Department of Biochemistry, University of Lausanne,  
Epalinges, Switzerland. 8Department of Dermatology, University Hospital CHUV, Lausanne, Switzerland.
Downmodulation or loss-of-function mutations of the gene encoding NOTCH1 are associated with dysfunc-
tional squamous cell differentiation and development of squamous cell carcinoma (SCC) in skin and internal 
organs. While NOTCH1 receptor activation has been well characterized, little is known about how NOTCH1 
gene transcription is regulated. Using bioinformatics and functional screening approaches, we identified sev-
eral regulators of the NOTCH1 gene in keratinocytes, with the transcription factors DLX5 and EGR3 and 
estrogen receptor β (ERβ) directly controlling its expression in differentiation. DLX5 and ERG3 are required 
for RNA polymerase II (PolII) recruitment to the NOTCH1 locus, while ERβ controls NOTCH1 transcription 
through RNA PolII pause release. Expression of several identified NOTCH1 regulators, including ERβ, is fre-
quently compromised in skin, head and neck, and lung SCCs and SCC-derived cell lines. Furthermore, a kerati-
nocyte ERβ–dependent program of gene expression is subverted in SCCs from various body sites, and there are 
consistent differences in mutation and gene-expression signatures of head and neck and lung SCCs in female 
versus male patients. Experimentally increased ERβ expression or treatment with ERβ agonists inhibited pro-
liferation of SCC cells and promoted NOTCH1 expression and squamous differentiation both in vitro and 
in mouse xenotransplants. Our data identify a link between transcriptional control of NOTCH1 expression 
and the estrogen response in keratinocytes, with implications for differentiation therapy of squamous cancer.
Introduction
Squamous cell carcinomas (SCCs) are the most common form 
of human solid tumors and a major cause of cancer lethality. 
These highly heterogeneous tumors arise from closely intercon-
nected epithelial cell populations with substantially different 
self-renewal potential and a highly synchronized program of 
stratified differentiation. NOTCH signaling plays a pivotal role in 
diverse developmental, physiological. and pathological processes 
(1). Among the 4 known NOTCH receptors, NOTCH1 plays the 
most significant role in squamous cell differentiation (2). Recent 
whole-genome sequencing studies identified recurrent loss-of-
function mutations of the NOTCH1 gene in head and neck (H/N), 
cutaneous, lung, and esophageal SCCs (3–7), consistent with the 
tumor-suppressing function that NOTCH1 activation can play in 
this tumor type (8). Most attention has been given to its opposite 
tumor promoting function in other malignancies, such as T cell 
leukemia (T-ALL) (9) and breast cancer (10). While current drug 
development attempts are focused on inhibiting NOTCH signal-
ing, it would also be desirable to identify approaches for activa-
tion of this pathway for possible differentiation-based therapy of 
squamous cancer.
Control of NOTCH1 activity has been highly studied at the level 
of receptor processing and activation, while surprisingly little is 
known of direct transcription control of the NOTCH1 gene (1). We 
and others have shown that NOTCH1 is a direct p53 target in kera-
tinocytes and that its downmodulation in keratinocyte-derived 
tumors can be explained, in part, by mutation or downmodula-
tion of p53 expression (11, 12). In most cells, with the notable 
exception of T cells (13), transcription of the human NOTCH1 
gene is driven by a single TATA-less “sharp peak” promoter that, 
in human keratinocytes, is under synergistic negative control of 
KLF4 and Sp3 (14). A related but more complex mode of regula-
tion has been reported in human esophageal cancer cells, in which 
NOTCH1 transcription appears to be under positive KLF5 control 
as a compensatory mechanism to compromised p53 function (15). 
A few other transcription factors have been reported to control 
NOTCH1 transcription in different cell types, including Ovol2 
(16), FOXN1 (17), STAT3 (18), E2A (19), NF-κB (20), and HIF1α 
(20). While these studies were focused on involvement of individ-
ual transcription factors, to the best of our knowledge, no studies 
have been undertaken to probe into transcriptional control of the 
NOTCH1 locus in a more systematic manner.
By a combined bioinformatic and functional screening approach, 
we have identified 3 direct regulators of the NOTCH1 gene: DLX5, 
a homeobox protein best known for its role in proximal-distal 
limb development (21); EGR3, an immediate early response gene 
involved in neuronal plasticity (22); and estrogen receptor β (ERβ), 
whose biological and biochemical functions are much less estab-
lished than those of its cousin, ERα (23). Altered estrogen signal-
ing is involved in development of a number of cancers, including 
breast, ovarian, colorectal, prostate, and endometrial cancers, and 
this pathway has been intensively investigated for pharmacological 
targeting (24). In breast cancer, there have been various reports on 
interplay between the NOTCH1 and estrogen/ERα signaling path-
ways at multiple levels (refs. 25, 26, and refs. therein), but none on 
NOTCH1 as an ERα transcriptional target. Global gene expres-
sion analysis combined with ChIP-seq studies has revealed that 
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Figure 1
Identification of transcription factors that control NOTCH1 expression in HKCs. (A and B) Two different HKC strains were reverse transfected with 
siRNAs against the indicated set of transcription factor genes, with siRNAs against NOTCH1 and p53 (top 2 lines) as control for effectiveness of 
the assay. Three different siRNAs per gene were tested (si1–si3), each in triplicate wells. One week after transfection, HKCs were analyzed by 
RT-qPCR for levels of NOTCH1 and HEY1 expression, with 36β4 for normalization. Results are expressed as heat map of log2 ratios relative to 
cells transfected with scrambled siRNA control. Arrows indicate genes selected for further validation. (C) Validation of the above results for the 
indicated set of genes by reverse transfection of a third independent strain of HKCs, utilizing the same conditions as before. RT-qPCR analysis 
was used to assess siRNA KD efficiency of each gene and impact on levels of NOTCH1 primary and mature transcripts and other NOTCH path-
way components. (D and E) RT-qPCR (D) and immunoblot analysis (E) of expression of the indicated genes in HKCs under proliferative conditions 
(70% confluence [cf]) and at various time (days [D]) of differentiation induced by high cell density. FL, full length; NEXT, NOTCH extracellular 
truncation, ICD, intracellular domain. mRNA levels were normalized for 36β4 and presented as fold-changes relative to cells under proliferative 
conditions. **P < 0.007; ***P < 0.001. Similar results were obtained with analysis of an independent strain of HKCs (Supplemental Figure 2A). For 
detailed blot information, see complete unedited blots in the supplemental material.
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ERα and ERβ have both common and distinct target genes (27). 
However, since most ERβ studies were generated using ectopically 
expressed protein, characterization of endogenous ERβ transcrip-
tional function is still missing. Our findings establish that ERβ, 
like EGR3 and DLX5, is a direct positive regulator of NOTCH1 
expression in keratinocytes and keratinocyte-derived SCC cells. We 
point to this molecule as a possible therapeutic target for differ-
entiation therapy treatment of SCC. In fact, ERβ expression and 
function, linked with NOTCH1-dependent differentiation, are fre-
quently compromised in skin, H/N, and lung SCCs, and increased 
ERβ expression or pharmacological treatments with ERβ agonists 
can suppress proliferation of SCC cells both in vitro and in vivo, 
while promoting NOTCH1 expression and differentiation.
Results
A transcription factor network involved in control of NOTCH1 gene 
expression in keratinocytes. To probe into transcription control of 
the NOTCH1 gene, we started by examining the chromatin con-
figuration of the human NOTCH1 locus in human primary kerati-
nocytes (HKCs) utilizing whole genome information provided by 
the ENCODE consortium (http://genome.ucsc.edu/ENCODE/). 
Since insulator elements segregate genomic regulatory units, 
we focused on the NOTCH1 region delimited by peaks of ChIP 
sequencing (ChIP-seq) for the insulator protein CTCF. We further 
focused on chromatin regions of likely regulatory function on the 
basis of ChIP-seq peaks for modified histones present in enhancers 
and promoters. Sixty transcription factors with putative binding 
sites within these regions were selected for functional screening on 
the basis of their conservation among rat, mouse, and human and/
or their epithelial pattern of expression in normal versus patho-
logical conditions (as indicated by EST and cDNA microarray 
databases) (Supplemental Table 1; supplemental material avail-
able online with this article; doi:10.1172/JCI72718DS1).
A custom-made siRNA library was utilized to knock down (KD) 
expression of these genes in HKCs by reverse transfection. The pri-
mary screen was performed twice, with 3 siRNAs per gene, utilizing 
2 HKC strains of independent origin. For both screens, cells were 
collected 1 week after transfection, i.e., under high-density differ-
entiating conditions associated with elevated NOTCH1 expression 
(11) to capture factors involved in NOTCH1 transcription activa-
tion. Successful assay conditions were verified by assessing the 
impact on NOTCH1 mRNA levels of siRNA-mediated KD of the 
NOTCH1 gene itself as well p53 as a known positive regulator of 
NOTCH1 expression (ref. 11 and Figure 1, A and B). In parallel with 
NOTCH1, we assessed expression of the “canonical target gene” 
HEY1 as an indicator of endogenous NOTCH activity (11). Fifteen 
genes with consistent KD-mediated effects on NOTCH1 and HEY1 
expression (>1.8-fold up- or downmodulation) in the 2 primary 
screens were further validated by siRNA KD in a third strain of 
HKCs (Figure 1C). In parallel with the mature NOTCH1 mRNA, we 
assessed levels of the primary transcript (by quantitative RT-PCR 
[RT-qPCR] of the third exon-intron junction) as well as transcripts 
of other key components of the NOTCH pathway. KD of STAT3, a 
tumor-promoting gene in keratinocytes (28), and PLAG1, a gene of 
unknown function in keratinocytes with a versatile role in tumor 
development (29), caused upregulation of the mature NOTCH1 
mRNA and downregulation of the primary transcript, implicat-
ing these genes in opposite control mechanisms of NOTCH1 tran-
scription and mRNA stability (Figure 1C). KD of all other genes 
resulted in a similar downregulation of both mature and primary 
NOTCH1 transcripts, indicating that they function mostly at the 
level of transcription. Interestingly, expression of other NOTCH-
signaling components was differentially affected by silencing of 
the various genes, in many cases in a manner opposite of that of 
NOTCH1, indicating that expression of these various components 
can be genetically dissociated (Figure 1C).
To assess whether NOTCH1 regulators are themselves under 
NOTCH-signaling control, we evaluated their expression in 
HKCs upon NOTCH1 KD or activation of the endogenous recep-
tor by coculture with fibroblasts expressing the NOTCH ligand 
Jagged-2. Expression of most genes did not change consistently 
under the 2 conditions (Supplemental Figure 1A). Given the 
positive role of p53 in control of NOTCH1 expression (11, 12), 
we also examined expression of the identified NOTCH1 regula-
tors in HKCs with p53 KD or stabilization of the endogenous 
p53 protein by Nutlin-3a treatment. Only ZEB1, which plays a 
significant role in epithelial-mesenchymal transition in other 
cellular systems (30), was consistently modulated in both condi-
tions (Supplemental Figure 1B).
EGR3, DLX5, and ERβ activate NOTCH1 gene transcription during dif-
ferentiation. The transcription factors identified in our screen may 
fulfill 2 functions, i.e., be required for maintenance of sustained 
transcription and/or play a more direct positive role in control of 
the NOTCH1 gene. We reasoned that transcription factors involved 
in positive control of NOTCH1 expression might be concordantly 
upregulated with differentiation. Among the 15 NOTCH1 regu-
lators, EGR3, DLX5, and ERβ (encoded by the ESR2 gene) were 
consistently upregulated during differentiation (Figure 1, D and 
E, and Supplemental Figure 2). To assess whether these 3 factors 
participated directly in transcription control of the NOTCH1 gene, 
ChIP assays were performed with extracts of total human epider-
mis. The results showed binding of all 3 factors to the NOTCH1 
locus at distinct regulatory regions: EGR3 was detected at a single 
enhancer region (E3) 6.5 kB upstream of the transcription start 
site (TSS); DLX5 was found at the promoter region and at a down-
stream enhancer (E1); and ERβ was detected at the promoter 
region (P) as well as at upstream (E9) and downstream (E1, E2) 
enhancers, with apparently greater binding to the latter (Figure 
2B and Supplemental Figure 3A). Similar ChIP assays were per-
formed on HKCs in culture conditions that allowed study of the 
transition from proliferation to early steps of differentiation. This 
time-course analysis showed that the binding of these factors in 
HKCs underwent dynamic change from growing to differentiat-
ing conditions, with enhanced binding of the 3 factors to the cor-
responding regions of the NOTCH1 locus in differentiating HKCs. 
In these cells, besides the upstream E3 enhancer, EGR3 binding to 
the NOTCH1 promoter region was also detected. DLX5 was found 
to bind to the promoter region of the NOTCH1 gene but not to 
the downstream enhancer. ERβ was found at multiple regions of 
the NOTCH1 locus that overlapped to a large extent with those 
detected in the epidermis, plus additional upstream enhancers 
(E6, E7) (Figure 2C and Supplemental Figure 3B). Binding speci-
ficity of each factor was confirmed by ChIP analysis performed 
on high-density differentiating HKCs plus/minus KD of EGR3, 
DLX5, and ERβ expression (Figure 2D, Supplemental Figure 3C, 
and Supplemental Figure 4A).
EGR3 and DLX5 are required for RNA PolII recruitment to the 
NOTCH1 locus and ERβ for RNA PolII pause release. For further 
functional insights, growing versus differentiating keratinocytes 
were subjected to ChIP with antibodies against RNA polymerase 
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II (PolII) as well as histone modifications associated with active 
promoter (H3K4me3 and H3K27ac) and enhancer (H3K4me1 
and H3K27ac) regions. PolII binding increased with differentia-
tion in parallel with the active chromatin histone marks, not only 
at the promoter and downstream enhancer regions, but also at 
some upstream enhancers (E3–E6), which may be the result of 
promoter-enhancer interactions and “chromosome looping” (ref. 
31, Figure 3A, and Supplemental Figure 4B).
Figure 2
Binding of endogenous EGR3, DLX5, and ERβ to NOTCH1 gene locus in human epidermis and HKCs. (A) Schematic representation of NOTCH1 
gene locus. CTCF: insulator elements. Black bars, exons; gray boxes, predicted enhancer (E1–E9) and promoter (p) regions; black arrows, pre-
dicted binding regions of DLX5, EGR3, and/or ERα/β (nucleotide locations in brackets). (B) ChIP assays of EGR3, DLX5, and ERβ binding to the 
corresponding predicted sites of the NOTCH1 locus in intact human epidermis. All ChIP samples were examined in parallel by PCR amplification of 
a negative control region (NR) located between enhancers 8 and 9 of the NOTCH1 locus and devoid of predicted EGR3-, DLX5-, and ERβ-binding 
sites. Results are expressed as fold of enrichment for each indicated binding site relative to the negative control region. Statistical significance 
was determined by unpaired Student’s t test (*P < 0.05). (C) ChIP assays of EGR3, DLX5, and ERβ binding to the NOTCH1 locus in HKCs under 
growing (70% confluence) versus differentiating (100% confluence) conditions. ChIP assays were performed and data analyzed as in B (*P < 0.05). 
Enrichment folds in the immunoprecipitates with nonimmune IgGs were in all cases less than 1. (D) ChIP assays of endogenous EGR3, DLX5, and 
ERβ binding to the NOTCH1 locus in differentiating HKCs (100% confluence) with or without individual KD of the 3 genes. Results were analyzed 
as in B (*P < 0.05). Results similar to those in B–D were obtained with HKCs of independent origin; see also Supplemental Figure 3, A–C.
Downloaded from http://www.jci.org on February 13, 2015.   http://dx.doi.org/10.1172/JCI72718
research article
2264 The Journal of Clinical Investigation   http://www.jci.org   Volume 124   Number 5   May 2014
PolII binding at promoter and enhancer regions was substan-
tially decreased in differentiating HKCs in which DLX5 and EGR3 
genes were KD (Figure 3B). KD of ERβ had more complex and 
unexpected consequences. In HKCs with ERβ downmodulation, 
binding of PolII to the downstream transcribed region of the 
NOTCH1 gene was, as expected, decreased, while binding to the 
promoter and 2 of the upstream enhancers (E4, E5) was increased 
rather than decreased (Figure 3B and Supplemental Figure 4C). 
This suggests that the presence of ERβ is required for progression 
of PolII through the transcribed downstream region and that, in 
its absence, PolII is still recruited to the gene, but kept in a paused 
state that is known to also have consequences on “looping” (32).
In genomic regions of active transcription or pausing, elevated 
PolII is associated with active chromatin configuration, whereas 
reduction in PolII recruitment leads to nucleosome reassembly and 
less open configuration (32). Consistent with the suppression of 
NOTCH1 gene transcription, H3K4me1 levels at the downstream 
enhancers (E1 and E2) were decreased in differentiating keratino-
cytes with DLX5, EGR3, or ERβ KD (Figure 3C and Supplemental 
Figure 4C). Interestingly, at the promoter region, levels of H3K4me3 
and H3K27ac, as signs of open configuration, were either decreased 
(H3K4me3) or unaffected (H3K27ac) in HKCs with DLX5 and 
EGR3 KD, while they were substantially increased in HKCs with 
ERβ KD (Figure 3C and Supplemental Figure 4D). Substantially 
increased H3K27ac was also found at 2 upstream enhancer regions 
(E4 and E5) in HKCs with ERβ KD, which paralleled increased PolII 
binding even at these locations (Figure 3C and Supplemental Figure 
4D). Repressive marks, such as H3K9me3 and H3K27me3, were not 
enriched at any of the regulatory regions (E1–E9) in either control 
or KD conditions, and levels of other modified histone marks (such 
as H3K4me1 and H3K9ac) were not consistently altered in the 2 dif-
ferent strains of HKCs that were tested (data not shown).
DLX5 and ERβ induce keratinocyte differentiation through a NOTCH-
dependent mechanism. NOTCH signaling plays an important pro-
differentiation role in keratinocytes (2). To determine whether 
EGR3, DLX5, and ERβ function as positive determinants of dif-
ferentiation, several complementary approaches were undertaken. 
In the first, we found that KD of these genes by lentiviral-medi-
ated shRNA delivery caused, in parallel with decreased NOTCH1 
expression, downmodulation of differentiation markers such as 
keratin 1 and 10, which was rescued to a large extent by exogenous 
activated NOTCH1 expression (Figure 4, A and B, and Supplemen-
tal Figure 5, A–C). The impact on differentiation was further eval-
uated by assessing behavior of HKCs in skin organotypic cultures 
in which they underwent a vertical differentiation program closely 
approximating that occurring in vivo (11). Even under these condi-
tions, DLX5, ERβ, and EGR3 KD resulted in a significant reduc-
tion of NOTCH1 expression, as assessed by immunoblot analysis 
of proteins recovered from the reconstituted epidermis as well 
as by immunofluorescence analysis (Figure 4, C–E, and Supple-
mental Figure 5, D and E). Epidermal reconstitution capability of 
HKCs was not affected by EGR3 silencing, while KD of DLX5 and, 
to a greater extent, ERβ resulted in a reduced number of strati-
fied layers and defective cornification and terminal differentiation 
marker expression (Figure 4D and Supplemental Figure 5, D and 
E), causing effects similar to those resulting from NOTCH inhibi-
tion in keratinocyte 3D cultures (33).
For a complementary gain-of-function approach, we assessed 
whether increased expression of the EGR3, DLX5, and ERβ pro-
teins via retroviral vector transduction to levels comparable to 
those found with differentiation was sufficient to induce NOTCH1 
mRNA and protein expression (Figure 5A and Supplemental Figure 
6A). Interestingly, immunoblot analysis with antibody against the 
intracellular activated form of NOTCH1 (NOTCH1 ICD) showed 
enhanced NOTCH1 activation only in HKCs with increased DLX5 
and ERβ but not EGR3 expression (Figure 5A and Supplemental 
Figure 6B), suggesting that additional posttranscriptional events 
required for NOTCH1 activation are also induced by the first 2 reg-
ulators but not the third. Consistent with these findings, enhanced 
expression of DLX5 and ERβ, but not EGR3, led to induction of 
the canonical NOTCH target HEY1 as well as the differentiation 
marker involucrin, which was prevented to a large extent by con-
comitant inhibition of NOTCH activation by treatment with the 
γ-secretase inhibitor DAPT or NOTCH1 KD (Figure 5B). Interest-
ingly, increased EGR3, DLX5, and ERβ levels had different effects 
on expression of cell cycle and proliferation marker genes. While 
increased ERβ expression did not elicit any changes, elevated EGR3 
and DLX5 expression downregulated Ki67 and cyclin E2 levels and 
induced p21WAF1/CIP1, consistent with the fact that keratinocyte dif-
ferentiation and cell-cycle control can be separately controlled (ref. 
34 and Figure 5C).
Deregulated expression of NOTCH1 regulators in SCC of skin, H/N, and 
lung. Consistent with its tumor suppressor function, the NOTCH1 
gene is downregulated or mutated in a significant fraction of skin, 
H/N, and lung SCCs (3, 6, 7, 11). Analysis of gene-expression pro-
files of these tumors from different data sets confirmed the fre-
quent downmodulation of NOTCH1, along with upregulation of 
genes under negative NOTCH control in keratinocytes, such as 
p63, integrin α6, and integrin β4 (Figure 6A). Expression of “canon-
ical” NOTCH targets of the HES/HEY family was variously modu-
lated, consistent with their capability to crossregulate each other 
and their regulation by other input signaling pathways (35–38). In 
particular, HES1 expression was commonly decreased in skin and 
H/N SCCs, HEY1 was downmodulated in the first set of tumors 
and upregulated in the second, and both HES1 and HEY1 were 
increased in lung SCCs (Figure 6A).
Many transcription factor genes identified in our screen as mod-
ulators of NOTCH1 expression were also deregulated in SCCs, with 
closer variations in skin and H/N SCCs than in lung SCCs. While 
EGR3 was commonly downmodulated in tumors from the 3 body 
sites, DLX5 was variably expressed. ESR2 expression was decreased 
in skin and lung SCCs, while another NOTCH1 regulator that is 
required for ER binding to target DNA, PBX1 (39), was downmodu-
lated in many skin and H/N SCCs and, more variably, in lung SCCs 
(Figure 6A). Expression of the EGR3, DLX5, and ERβ proteins was 
found decreased by immunohistochemical analysis of a large set 
of skin SCCs on tissue arrays (Figure 6B). Decreased expression of 
these genes was also seen by immunoblot analysis of a number of 
skin, H/N, and lung SCC cell lines (Figure 6, C and D).
ERβ and sex-related gene-expression signatures and mutations in 
SCCs. Given the translational potential, for further studies 
we focused on ERβ. We assessed at first the global impact of 
decreased ERβ signaling on the transcriptional program of pri-
mary keratinocytes and to what extent these changes in gene 
expression overlap with those in clinically occurring SCCs. 
cDNA microarray analysis of HKCs with and without ERβ KD 
confirmed that genes related to epidermal differentiation were 
downregulated in HKCs with silenced ERβ expression (Supple-
mental Table 3). Besides ER-dependent genes, other gene fami-
lies significantly downmodulated in these cells included genes 
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involved in stress response and positive regulation of transcrip-
tion, while other stress-response genes, genes involved in pro-
liferation, wounding, cell migration, and angiogenesis were 
upregulated (Supplemental Table 3). A substantial fraction of 
genes within these families were similarly deregulated in gene 
expression profile studies of lung, H/N, esophageal, and skin 
SCCs (Figure 7A and Supplemental Table 4). Interestingly, genes 
in other families were oppositely regulated in the ERβ-silenced 
HKCs versus clinical SCCs. These include a class of genes 
involved in DNA packaging and nucleosome assembly, lipid 
and estrogen metabolic processes, and a less defined category of 
genes related to “system development.”
Epidemiologic studies indicate that there is a greater risk of skin, 
H/N, and lung SCCs in the male versus female populations, which 
may not be simply due to differences in lifestyle (40). For further 
insights, we examined the results of next-generation sequencing 
studies of H/N (The Cancer Genome Atlas, https://tcga-data.nci.
nih.gov/tcga/; Peter S. Hammerman, personal communication, and 
Figure 3
Essential role of EGR3, DLX5, and ERβ in RNA PolII recruitment to the NOTCH1 locus and/or pause release. (A) ChIP analysis of HKCs under growing 
versus differentiating conditions for levels of PolII occupancy of the NOTCH1 locus and associated levels of active histone marks of active promoter 
(H3K4me3, H3K27ac) and/or enhancer (H3K4me1, H3K27ac) regions. All ChIP samples were examined in parallel by PCR amplification of a negative 
control locus (NL) in chromosome 4, devoid of active chromatin marks and utilized for similar normalization purposes in previous studies with a number 
of cell types. Enrichment folds were calculated and plotted as in Figure 2 (*P < 0.05). Enrichment folds in the immunoprecipitates with nonimmune 
IgG were in all cases less than 1. Similar patterns of PolII binding were obtained with HKCs of independent origin; see also Supplemental Figure 4B. 
(B) HKCs transfected with siRNA against EGR3, DLX5, or ERβ versus siRNA controls were processed 96 hours later (at 100% confluency) for ChIP 
assays of levels of PolII occupancy of the NOTCH1 locus. For ease of representation, levels of PolII binding in cells with KD of the individual genes 
are separately shown, utilizing PolII levels in control cells as the same point of reference (*P < 0.05). (C) HKC samples utilized in B were analyzed in 
parallel by ChIP assays for levels of active histone marks at the NOTCH1 promoter and enhancer 1, 2, 4, and 5 regions (*P < 0.05). Results similar to 
those in A–C were obtained with HKCs of independent origin; see also Supplemental Figure 4D. 
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Figure 4
Silencing of EGR3, DLX5, and ERβ leads to attenuation of NOTCH1 expression and differentiation. (A) HKCs infected with shRNAs silencing len-
tiviruses versus control were analyzed 96 hours later by immunoblotting. Gene KD efficiency was assessed by parallel blots of those for NOTCH1 
and Keratin 1 expression. Similar results were observed at the NOTCH1 mRNA level and in another experiment with HKCs of independent origin 
(Supplemental Figure 5). (B) HKCs infected with lentiviruses as in A were superinfected with retrovirus expressing NOTCH1 intracellular domain 
fused to the human estrogen receptor (rNert), or vector control (Neo). 24 hours later, cultures were treated with OH-tamoxifen (OH-TAM) for 48 
hours for nuclear NOTCH1 intracellular domain translocation. Expression of Keratin genes was determined by RT-qPCR (*P < 0.02). Results simi-
lar to those were obtained with a second HKC (Supplemental Figure 5C). (C–E) HKCs infected with lentiviruses as in A were grown in duplicate 
dermal equivalent gels at air-liquid interface for 12 days. The experiment was performed twice. (C) Immunoblot analysis of full-length NOTCH1 
expression in reconstituted epidermis with signal quantification (numbers) by densitometric scanning and γ-tubulin normalization. (D) H&E 
analysis showing defective stratification and cornified layer formation in organotypic cultures with ERβ and DLX5 KD HKCs. Scale bar: 100 μm. 
H&E images of other cultures and immunofluorescence analysis of differentiation marker expression are shown in Supplemental Figure 5D. 
(E) Immunofluorescence analysis of NOTCH1 expression in the reconstituted epidermis. For each series, image-capture conditions were the 
same. Scale bars: 50 μm. Images are representative of 3 independent fields.
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TCGA Network) and lung SCCs (5) that could be divided between 
female and male patients. Surprisingly, among genes mutated in 
at least 10% of SCCs, a number exhibited a statistically significant 
difference in mutation frequency between the 2 sexes (Figure 7B 
and Supplemental Table 5). Most of these genes have cell regula-
tory functions that will be interesting to evaluate in the context of 
estrogen and/or sex-related signaling events. As a complementary 
approach, we examined whether there may also be differences in the 
global gene expression profiles of the same set of H/N SCCs ana-
lyzed for gene mutations in The Cancer Genome Atlas. A substantial 
number of genes were differentially expressed in SCCs from patients 
of the 2 sexes, including, as expected, Y- and X-linked genes (Figure 
7C and Supplemental Table 6). Importantly, several genes related 
to the squamous differentiation program were significantly more 
expressed in SCCs of female patients, including those coding for 
desmoglein 1, caspase 14, psoriasin (S100A7), and defensins as well 
as cornified envelope proteins (Figure 7C).
ERβ is a positive determinant of NOTCH1 gene expression and function 
in SCC cells. To directly assess the impact of increased ERβ signal-
ing in SCC outgrowth, a panel of skin, oral, and lung SCC cell lines 
was infected with ERβ-expressing versus control viruses. As shown 
in Figure 8A, proliferation of most cell lines, as assessed by Ala-
mar blue cell density assays, was significantly inhibited as a con-
sequence of ERβ overexpression. Cells with elevated proliferative 
potential, as assessed by colony or sphere formation assays, were 
also significantly reduced (Figure 8, B–E, and Supplemental Figure 
7). Increased ERβ expression in many SCC cell lines derived from 
various body sites was accompanied by upregulation of NOTCH1 
and differentiation marker expression (Figure 9A), with induction 
of the latter being significantly counteracted by DAPT treatment 
(Figure 9B). To test the in vivo impact of increased ERβ expres-
sion, representative cell lines from skin (SCC13), H/N (SCCO13), 
and lung SCCs (H2170) were assessed by intradermal tumorigenic-
ity assays in immunocompromised mice (41). Tumors formed by 
cells with increased ERβ expression reached a size similar to that of 
controls, but with enhanced NOTCH1 expression and differentia-
tion (Figure 9, C and D, and Supplemental Figure 8).
Besides estrogen, other agonists have been developed with elevat-
ed specificity for either the ERα or ERβ receptors (42). Use of these 
molecules could be of substantial translational interest as induc-
ers of squamous cell differentiation and SCC tumor suppression. 
Treatment of HKCs with either 17β-estradiol (E2) or 2,3-bis(4-
hydroxyphenyl)-propionitrile (DPN), an ERβ selective agonist (42), 
resulted in induction of NOTCH1 expression as well as differen-
tiation marker expression (Figure 10A). Little or no induction was 
observed after treatment with 1,3,5-Tris(4-hydroxyphenyl)-4-pro-
pyl-1H-pyrazole (PPT), an ERα-selective agonist, while NOTCH1 
as well as differentiation marker expression was suppressed by 
Figure 5
EGR3, DLX5, and ERβ as regulators of NOTCH1 expression and function in HKCs. (A) HKCs under sparse conditions were infected with retro-
viruses expressing EGR3, DLX5, or ERβ versus empty vector controls as indicated, followed 72 hours later (at approximately 80% confluence) 
by immunoblot analysis for levels of these proteins as well as the full-length NOTCH1 protein (NOTCH1 FL) and the intracellular activated form 
(NOTCH1 ICD). HKCs under differentiating conditions (100% confluence for 3 days: 100% cf+3D) were analyzed in parallel as point of reference. 
Similar results were observed at the RNA level and in other experiments with HKCs of independent origin (Supplemental Figure 6, A and B). (B) 
HKCs with or without infection with EGR3-, DLX5-, and ERβ-expressing retroviruses as in the previous panel were treated with DAPT (10 μM) or 
DMSO control at 24 hours after infection followed, 48 hours later, by RT-qPCR analysis of involucrin gene expression, with 36β4 for normaliza-
tion. As an alternative, HKCs stably infected with a shRNA lentivirus against NOTCH1 or empty vector control were superinfected with the EGR3, 
DLX5, and ERβ expressing retroviruses, followed 72 hours later by RT-qPCR analysis of the same genes. (C) HKCs with or without infection with 
EGR3-, DLX5-, and ERβ-expressing retroviruses as in A were analyzed, 72 hours after infection, by RT-qPCR of the indicated genes. *P < 0.001.
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treatment with fulvestrant, a complete ER antagonist (42, 43) 
(Figure 10A). Analysis of SCC gene expression profiles indicated 
that the CYP1B1 gene, coding for a hydroxylases of the P450/CYP1 
family with a key role in estrogen inactivation and procarcinogenic 
conversion (44), was frequently overexpressed in SCCs (Figure 7A 
and Supplemental Table 4). Increased CYP1B1 expression was also 
found in the panel of SCC cell lines used in this study (Figure 10B). 
These cells exhibited different dose sensitivities to DPN treatment, 
but in all cases, their proliferation and sphere-forming capability 
were suppressed (Figure 10, C and D), in parallel with induction 
of NOTCH1 and differentiation marker expression (Figure 10E). 
As an in vivo test, a cohort of mice was intradermally injected with 
SCCO13 cells, followed by daily administration of DPN or DMSO 
vehicle alone. Relative to controls, mice treated with the ERβ-
Figure 6
Deregulated expression of EGR3, DLX5, and ERβ and other NOTCH1 regulators in cutaneous, H/N, and lung SCCs. (A) Heat map of transcrip-
tomic data of the indicated set of genes in a set of skin SCCs versus normal epidermis (n = 10/3) analyzed in our own laboratory (GSE45164) and 
published data sets of H/N and lung SCCs versus normal tissue controls (E-GEOD-9844, n = 26/12; E-GEOD-23558, n = 27/5) (Bhattacharjee 
Lung, n = 21/17; Garber Lung, n = 13/6; Hou Lung, n = 27/65; Talbot Lung, 34/28; Wachi Lung, n = 5/5). (B) Immunohistochemical analysis of 
EGR3, DLX5, and ERβ expression in tissue arrays of in situ and invasive skin SCCs versus normal skin (n = 31, 226, 10, respectively). Repre-
sentative staining is shown along with quantification of percentage of positive nuclei (DLX5) or immunoreactivity (EGR3 and ERβ) as indicated. 
Error bars represent mean ± SEM. Statistical analysis was performed using 1-way ANOVA. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001. 
Original magnification, ×14.4. (C) Skin (SCC12 and SCC13) and H/N SCC cell lines (Cal27, Cal33, FaDu, SCCO11, SCCO13, SCCO22, and 
SCCO28) were analyzed with HKCs under growing conditions by immunoblotting. (D) Indicated lung SCC cell lines were analyzed in parallel 
with HBECs for NOTCH1, EGR3, DLX5, and ERβ expression by immunoblotting. For detailed blot information, see complete unedited blots in 
supplemental material. 
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selective agonist exhibited tumors of significantly smaller size and 
reduced proliferative index (Figure 11A), with increased NOTCH1 
and differentiation marker expression (Figure 11, B and C).
Discussion
Recent advances in whole-genome analysis provide unique opportu-
nities to probe into coordinate control of gene expression and ensuing 
biological events. We have identified a transcriptional regulatory net-
work converging on control of NOTCH1 gene transcription in squa-
mous cell differentiation and cancer. Most of the transcription factors 
are themselves deregulated in skin, oral, and lung SCCs, with some 
undergoing gene mutations and/or rearrangements (3, 6, 7). Func-
tions of these factors, together with interactions of possible relevance, 
are summarized in Supplemental Table 2. While genetic and func-
tional evidence indicates that the NOTCH1 gene plays a prevalent role 
in keratinocyte differentiation and tumor suppression (8), the find-
ing of NOTCH2 and NOTCH3 mutations in SCCs (3–6) point to the 
possible importance of these genes for the disease. Their expression 
appears to be under distinct control mechanisms from NOTCH1, as 
they are oppositely regulated by most of the NOTCH1 regulators that 
we have identified. For further functional and biochemical studies, 
we focused on 3 factors that, as discussed here below, play a direct 
and positive role in NOTCH1 gene transcription in keratinocytes, with 
ERβ as a possible target of translational significance.
Figure 7
Comparative gene expression and mutation profiles of skin, H/N, and lung SCCs in relation to ER signaling and/or patients’ sex. (A) Expression 
profiles of ERβ-controlled genes in clinically occurring SCCs versus normal tissues. Microarray analysis of gene expression in HKCs plus/minus 
ERβ-KD identified genes under ERβ control (>1.5-fold change; Supplemental Table 3). Expression profiles of these genes were examined in clini-
cally occurring SCCs, utilizing our own and published data sets (Supplemental Table 4: Oncomine). Dark/light green and red columns on the right 
refer to the set of down- and upmodulated genes in HKCs with ERβ silencing that were found to be concordantly (dark colors) versus discordantly 
(light colors) regulated in clinically occurring SCCs in parallel with a differential gene family distribution (Supplemental Table 4). (B) Numbers of 
genes with mutations frequencies of 10% or more in lung and H/N SCCs from patients of one or both sexes (Fisher’s exact test < 0.05). Overlapping 
circles show numbers of genes with similar mutation frequency distribution in lung and H/N SCCs. For complete mutation gene list and analysis, 
see Supplemental Table 5. (C) Expression profiles of genes differentially expressed in female versus male H/N patients. Gene families with statisti-
cally significant enrichment are indicated on the left (Supplemental Table 6). Genes with a role in squamous differentiation are zoomed in. Log2 
expression values, median centered and divided by SD, are represented.
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EGR3 belongs to a family of 4 highly conserved zinc finger tran-
scription factors, originally identified in the “early response” of 
cells to growth factor stimulation (45). These proteins bind to the 
same consensus DNA sequence and can have a significant func-
tional overlap. They have been implicated in many biological pro-
cesses, including muscle and lymphocyte cell fate determination 
and neuronal development and plasticity (45). Little is known of 
functions of these genes in squamous differentiation, with EGR3-
deficient mice exhibiting little skin abnormalities, possibly due 
to functional compensation by other EGR family members (22). 
While EGR gene functions have been interconnected with impor-
tant signaling pathways, such as NF-κB, MAPK, and Calcineurin/
NFAT (46), a connection with NOTCH signaling, to our knowl-
edge, has not been reported. We have shown here that EGR3 func-
tions in keratinocytes as a direct positive regulator of NOTCH1 
gene expression, with endogenous EGR3 binding to the NOTCH1 
locus and being required for RNA PolII recruitment with differ-
entiation. Exogenous EGR3 expressed at levels similar to those 
found in differentiation was sufficient for induction of NOTCH1 
gene transcription. Interestingly, however, the increased levels of 
Figure 8
Elevated ERβ expression suppresses proliferation of skin, lung, and oral SCC cells. (A) Alamar blue cell density assays. Cell lines derived from 
skin (SCC13), H/N (Cal33, FaDu, SCCO11, SCCO13, SCCO28), and lung (H520, H2170, HCC95, SK-MES1, SW900) SCCs were infected with 
either an ERβ-expressing lentivirus (SCC13, SCCO13, and SCCO28) or retrovirus (all other cell lines) versus corresponding empty vector con-
trols, followed, 48 hours later, by G418 selection. Stably infected cells were plated in 96-well plates (2000 cells/well). Alamar blue fluorescence 
intensity assays were performed in triplicate every 2 days as indicated. Data are presented as mean fold change of fluorescence intensity ± SD 
over day 1. *P < 0.05. (B) Clonogenicity assays. Skin (SCC13) and H/N (SCCO13 and SCCO28) SCC cells infected with an ERβ-expressing 
lentivirus versus empty vector were plated at limited density on triplicate dishes (103 cells/60 mm dish), and colony formation was measured 
by crystal violet staining 10 days later. *P < 0.05. (C and D) Spheroid assays. Skin and H/N (C) and lung (D) SCC cells were infected with an 
ERβ-expressing retrovirus or lentivirus versus empty vector as in A. Stably infected cells were plated in duplicate in Matrigel suspension in 8-well 
chambers (2000 cells/well). Spheroid numbers were quantified 10 days later by digital acquisition of the whole well images and ImageJ software 
analysis. *P < 0.05. (E) Representative images of spheroids formed by SCCO11 cells infected with control versus ERβ-expressing retroviruses. 
Original magnification, ×2.5. Photographs of spheroids formed by other SCC cells are shown in Supplemental Figure 7B.
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been established. DLX5 belongs to the family of Distal-less (DLX) 
homeobox genes, identified for their role in distal limb develop-
ment (21). There are 6 family members, with different members 
having the potential of carrying out the same biological function 
in different species (21). Dlx5 and Dlx6 have been shown to play 
an important role downstream of p63 in the apical endodermal 
ridge and limb development (49). We have found that, in human 
keratinocytes, DLX5 functions as a direct positive regulator of 
NOTCH1 expression and exerts a prodifferentiation function that 
is, in part, NOTCH dependent. In the mouse system, Dlx3 may 
fulfill a similar function, as premature epidermal differentiation 
is induced by keratinocyte-specific Dlx3 overexpression (50), while 
Cre-mediated deletion of the gene results in epidermal hyperplasia 
NOTCH1 mRNA and protein resulting from EGR3 upregulation 
were not accompanied by a corresponding increase in the proteo-
lytically cleaved activated NOTCH1 protein. It has been recently 
reported that in keratinocytes, besides its increased expression, 
NOTCH1 activation depends on the parallel induction of one of 
its cleaving membrane-bound proteases (47). An interesting pos-
sibility is that EGR3 controls expression of NOTCH1, but not of 
other determinants of NOTCH activation, whose concomitant 
upregulation may instead account for NOTCH1 activation by 
DLX5 and ERβ discussed below.
Homeobox genes play a key role in development and cancer (48). 
Surprisingly, however, a direct connection between this important 
class of transcriptional regulators and NOTCH signaling has not 
Figure 9
Elevated ERβ expression induces NOTCH1 expression and differentiation. (A) SCC cell lines infected with ERβ-expressing viral vectors versus 
controls as in Figure 8 were analyzed for expression of the indicated proteins by immunoblotting. (B) SCC13 (skin), SW900 (lung), and SCCO13 
(oral) SCC cells infected with ERβ-expressing and control viral vectors were treated 24 hours after infection with DAPT (10 μM) or DMSO 
control followed, 72 hours later, by RT-qPCR analysis of involucrin and keratin 10 differentiation marker expression. *P < 0.05. (C) H2170 lung 
SCC cells infected with ERβ-expressing versus control vectors were injected intradermally in parallel in the right and left suprascapular regions 
of NOD/SCID mice (n = 5; 1 × 106 cells per injection). Animals were sacrificed 1 week later, and tumor samples were processed for H&E and 
immunofluorescence analysis of NOTCH1 expression. For each tumor pair, images were taken under the same capture conditions and are 
representative of several independent fields. Black scale bar: 500 μm; white scale bar: 100 μm. (D) SCC13 and SCCO13 cells infected with ERβ-
expressing versus control vectors were tested by parallel intradermal injections into mice as in C. Animals were sacrificed 3 weeks later, and tumor 
samples were processed for H&E and immunofluorescence analysis of NOTCH1 and differentiation marker expression as indicated. Analysis of 
other tumor pairs is shown in Supplemental Figure 8. Black scale bar: 250 μm; white scale bar: 100 μm.
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tive to ERα, the biochemical function of ERβ is less established, 
as it was mostly studied in cells with overexpression of the exog-
enous protein (27). Like EGR3 and DLX5, we have found that ERβ 
is induced and plays a direct positive role in control of NOTCH1 
expression in keratinocyte differentiation. Our further biochemi-
cal analysis revealed that, while both EGR3 and DLX5 are required 
for recruitment of RNA PolII to the NOTCH1 locus, ERβ is likely 
involved in pause release of this enzyme from the TSS. Following 
establishment of a transcription initiation complex, the onset of 
elongation is emerging as a highly regulated process for transcrip-
tion of many genes, especially with developmental and/or signal 
transduction functions (32). Control of NOTCH1 expression by 
RNA PolII pause release has not, to our knowledge, been previ-
ously reported. In breast cancer cells, ERα controls transcription 
through long-range “chromatin looping” (54) and is required for 
together with impaired hair follicle differentiation (51). Besides 
DLX5, another homeobox gene that was shown by our screen to 
be required for NOTCH1 expression is PBX1, which has previously 
been implicated in epidermal differentiation and barrier function 
(52). Of potential relevance for the present studies are findings in 
other systems that PBX proteins can form heteromeric complexes 
with DLX proteins (21) and that PBX1 can serve as a “pioneer fac-
tor” required for ER function as discussed below (39).
Estrogen receptors play a significant role in human physiology 
and disease, with a role extending to sex-unrelated organs, such as 
intestinal and cardiovascular systems (23, 24). The 2 main estro-
gen receptors, ERα and ERβ, are encoded by separate genes (ESR1 
and ESR2) and exhibit distinct tissue-specific patterns of expres-
sion. ERβ is the form predominantly expressed in human epider-
mal cells in vivo (53) as well as in culture (our observations). Rela-
Figure 10
ERβ agonists induce NOTCH1 and differentiation marker expression in HKCs and SCC cells with concomitantly attenuated proliferation. (A) Dif-
ferentiating HKCs (100% confluence) were treated with 10 nM estradiol (E2), 100 nM ERβ-specific agonist (DPN), 100 nM ERα-specific agonist 
(PPT), 10 nM estrogen receptor panantagonist (fulvestrant) or DMSO control followed, 72 hours later, by RT-qPCR (*P < 0.05) and immunoblot 
analysis of the indicated genes/proteins. For detailed blot information, see complete unedited blots in supplemental material. (B) Expression of 
CYP1B1 was determined by RT-qPCR in lung and keratinocyte-derived SCC cell lines in parallel with HBECs and HKCs, respectively. (C) Alamar 
blue density assays of SCC cells were performed in triplicate wells and treated with DPN or DMSO (refreshed every other day). Data are pre-
sented as mean fold change of fluorescence intensity ± SD (*P < 0.05). (D) Indicated SCC cells were plated in duplicate on Matrigel precoated 
chambers with spheroid number quantification 10 days later by ImageJ analysis of whole-cell images. Data are duplicates ± SD (*P < 0.05). 
Photographs and spheroid quantification of other SCC cells are shown in Supplemental Figure 9. (E) Indicated SCC cells were treated with the 
ERβ-specific agonist DPN at the indicated doses for 10 days. For detailed blot information, see complete unedited blots in supplemental material.
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sible differences in survival (58). A likely reason is the higher expo-
sure of the male population to procarcinogenic conditions such as 
smoking and alcohol abuse. However, estrogen receptor signaling 
may be a concomitant determining factor in this as well as in other 
organ diseases unrelated to reproductive function (40). Experi-
mentally, mice with abrogation of estrogen production by ovari-
ectomy or deletion of the ERβ gene had enhanced sensitivity to 
endogenous skin tumor development or transplanted skin tumor 
growth (59, 60). In apparent contrast, estrogen was reported to 
promote chemically induced lung carcinogenesis (61) and estro-
gen agonists have been generally reported to enhance proliferation 
and tumorigenicity of lung cancer cell lines (62). However, chemi-
cally induced mouse models reproduce the adenocarcinoma rath-
er than squamous carcinoma form of non–small cell lung cancer 
(NSCLC) (63), and the tested human cell lines were from lung ade-
nocarcinomas. Underlying their different histological properties, 
lung adenocarcinomas and squamous carcinomas have substan-
tially different genetic alterations and gene-expression signatures 
pause release of MYB gene transcription through recruitment of 
the P-TEFb kinase complex (55). In spite of intensive studies on 
the interconnection between ERα and NOTCH, direct binding 
and transcriptional control of the NOTCH1 gene by ERα has not 
been seen. Our findings indicate that ERβ instead carries out this 
function in keratinocytes and, possibly, beyond.
SCCs are notoriously resistant to conventional and targeted 
drug treatments, and novel differentiation therapy approaches, 
alone or in combination, may be of substantial value (56). Besides 
HKCs, we found that increased ERβ induces NOTCH1 expression 
and differentiation also in keratinocyte-derived skin and H/N SCC 
cells both in vitro and in vivo. Interestingly, ERβ-induced expres-
sion of NOTCH1 and squamous differentiation markers also 
occur in lung SCC lines, consistent with the capability of bron-
chial epithelial cells to undergo squamous cell differentiation as a 
possibly protective reaction against cancer development (57).
The incidence of clinically occurring SCCs in skin, H/N and lung 
is significantly higher in males than females, with associated pos-
Figure 11
ERβ agonist treatment delays SCC tumor growth and promotes differentiation. (A–C) SCCO13 cells were injected intradermally in the left supra-
scapular region of NOD/SCID mice (1 × 106 cells per injection). Forty-eight hours after injection, DPN was injected intraperitoneally into a cohort 
of mice (n = 5) at a dose of 20 mg/kg every day in parallel with another cohort of mice (n = 4) injected with DMSO vehicle alone. Animals were 
sacrificed 10 days later. Tumor weight and volume were measured, followed by determination of Ki67-labeling index by immunofluorescence 
analysis of histological section (A). *P < 0.05. Parallel immunofluorescence analysis was used to assess NOTCH1 and differentiation marker 
expression in all tumor samples, using same image capture conditions (B and C). Scale bar: 100 μm.
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Clonogenicity and Alamar blue assays were as reported (67). For spher-
oid assays, 8-well chamber slides were coated with Matrigel (BD Bioscienc-
es; 50 μl per well) and incubated at 37°C for 20 minutes to allow Matrigel 
to polymerize. SCC cells were brought into suspension in normal culture 
medium plus 1% Matrigel (7000 cells/ml) and added in triplicate to the 
precoated chamber slides (300 μl of cell mixture per well). Medium was 
refreshed every other day. For organotypic cultures, HKCs were infected 
with shRNA-expressing lentiviruses followed, 48 hours later, by selection 
for puromycin (2 μg/ml) resistance. Selected keratinocyte cultures were 
reseeded onto collagen gels with embedded J2-3T3 fibroblasts and cul-
tured at the air-liquid interface as previously described (68). After 12 days, 
epithelial sheets were peeled off the collagen lattice, snap-frozen, and pro-
cessed for immunoblot analysis, or embedded in tissue-freezing medium 
for immunohistochemical analysis, or fixed in 10% neutral buffered forma-
lin and embedded in paraffin for standard histology.
siRNA screen. A customized library (from Ambion) with 3 individual 
siRNAs for each selected gene was reversely transfected into HKCs in 
384-well plates (30 nM of each siRNA, tested in triplicate wells, in 0.8% 
HiPerFect (QIAGEN). HiPerFect was diluted in serum free medium (SFM) 
(Invitrogen) for 5 minutes before mixing with siRNAs diluted in the same 
medium. The mixture was incubated for 20 minutes at room temperature 
(RT) and then added to 384-well plates. Plates were spun down at 188 g 
for 5 minutes, and 5000 HKCs in medium without antibiotics were added 
to each well robotically. The plates were spun down at 188 g for 5 min-
utes again and then placed in a tissue culture incubator at 37°C with 5% 
CO2. Twenty-four hours after transfection, the transfection medium was 
removed and fresh HKC culture medium was added. At this time point, 
cells in each well were about 90%–100% confluent. Medium was changed 
every other day. One week after transfection, cells were cells were directly 
lysed in the wells, followed by RNA and cDNA preparation with a Fast-
Lane cell cDNA kit (QIAGEN) following the manufacturer’s instructions. 
siRNAs for DLX5, EGR3, and ERβ used for ChIP assays were purchased 
from Ambion/Invitrogen with the following specific sequences. EGR3: 
5′-AGAUCCACCUCAAGCAAAAtt-3′; DLX5: 5′-CAGAGAAGGUUU-
CAGAAGAtt; and ERβ 5′-CCUUACCUGUAAACAGAGAtt-3′.
RT-qPCR, immunodetection, and ChIP assays. Conditions for RT-qPCR, 
immunoblotting, immunofluorescence, and ChIP assays were as previ-
ously reported (11, 41). List of gene-specific primers and antibodies is pro-
vided in Supplemental Tables 7 and 8, respectively. For immunoblotting, 
unless otherwise indicated, cells were lysed in SDS sample buffer (50 mM 
Tris-HCl pH 6.8, 2% SDS, 10% glycerol, 0.2 unit nuclease), and protein sep-
aration was done in 15-well 4% to 12% NuPAGE Bis-Tris polyacrylamide 
gels (Invitrogen). Equal loading controls were done by reprobing the same 
immunoblots unless otherwise indicated. All assays were done at least 
twice, with 2 HKC strains or epidermal samples of independent origin.
Intradermal tumorigenicity assays. Lentivirally infected SCC13 and SCCO13 
cells and retrovirally infected H2170 cells were suspended in Matrigel fol-
lowed by intradermal injection (1.0 × 106 cells in 150 μl per injection) 
into the back skin of 6-week-old NOD/SCID mice (Taconic Farms Inc.) 
as described (11, 41). To minimize the individual animal variations, cells 
infected with control and ERβ-expressing viruses were injected in parallel 
in the right and left flanks of the same mice. Mice were sacrificed for tissue 
analysis 3 weeks (SCC13 and SCCO13) or 1 week (H2170) after injection. 
For ERβ agonist studies, SCCO13 cells were injected intradermally into 
NOD/SCID mice as described above. Forty-eight hours later, mice were 
randomly divided into 2 groups, one receiving DPN (20 mg/kg; DMSO 
stock solution diluted 1:33 in culture medium) and the other DMSO alone 
(also diluted 1:33 in culture medium), by daily intra-peritoneal injections 
for 10 days. Tumor volume was calculated using the following formula: 
volume = (width)2 × length/2.
(63), with loss of function NOTCH1 gene mutations occurring 
preferentially in the second type of tumors (5). The possibility that 
estrogen signaling also plays a tumor-suppressing function in the 
lung is supported by clinical epidemiological studies showing that, 
in postmenopausal women, estrogen exposure is associated with 
reduced risk of NSCLC (64) and nuclear ERβ expression is a posi-
tive prognostic marker for male NSCLC patients (65, 66).
Excitingly, taking advantage of recent next-generation sequenc-
ing data, we have uncovered a so-far unsuspected specificity of 
gene mutations in H/N and lung SCCs of female versus male 
patients, pointing to a possible molecular basis for differences of 
the disease between the 2 sexes. Such a possibility is further sup-
ported by our finding that SCCs of female and male patients can 
be discriminated on the basis of their gene expression program, 
with several squamous differentiation related genes and other 
gene families being differently expressed (Supplemental Table 
6). An attractive possibility raised by further functional studies is 
that estrogen-dependent control of NOTCH1 expression and dif-
ferentiation underlies these sex differences and that, by enhanc-
ing the squamous differentiation network that we have identified, 
estrogen mimetic compounds, in particular, ERβ-specific agonists, 
could be used in combination with other treatment modalities of 
premalignant and malignant lesions.
Methods
Cells, tissue samples, and viruses. HKCs and SCC (SCCO11, SCCO13, SCCO22, 
and SCCO28) cell lines were obtained and cultured as previously described 
(11, 41). Oral SCC cells (Cal27, Cal33, FaDu) were provided by Genrich 
Tolstonog (University Hospital of Lausanne). Human bronchial epithelial 
cells (HBEC) were purchased from ATCC. Lung SCC cells (H520, H2170, 
HCC95, SK-MES-1, and SW900) were provided by Peter S. Hammerman 
(Dana-Farber Cancer Institute, Boston, Massachusetts, USA). SCC sam-
ples were obtained at the Department of Dermatology of the University 
Hospital Zurich from clinical biopsies. Parts not needed for histological 
diagnosis were further processed with institutional review board approval.
Constructs for retro- and lentiviral production were obtained or made 
as follows. Retroviral vectors pMSCV-DLX5, pMSCV-EGFP-EGR3, rNERT-
neo, and Neo were provided by J.R. Testa (Fox Chase Cancer Center, Phila-
delphia, Pennsylvania, USA), W. Tourtelotte (Northwestern University Fein-
berg School of Medicine), and U. Just (Christian Albrechts University of 
Kiel, Kiel, Germany), respectively. pMXs-ESR2 was constructed by cloning 
the Flag-tagged full-length cDNA of ESR2 from pCXN2 vector (provided 
by S. Inoue, University of Tokyo, Tokyo, Japan) into the BamHI/NotI sites 
of the PMx vector using the following primers: forward, 5′-GATTCCG-
GATCCGCCACCATGGACTACAAGGACGACGATGACAAGGATATA-
AAAAACTCACCA-3′; and reverse, 5′-GCTGCTGCGGCCGCCTACTGAGA-
CTGTGGGTTCTG-3′. Lentiviral vectors of CSII-DLX5, CSII-EGR3, and 
CSII-ESR2 were constructed by cloning DLX5, EGR3, and ESR2 from retro-
viral vectors into CSII-EF-RfA-IRES2-Venus vector using Gateway cloning 
kits (Invitrogen). The following primers were used: DLX5 forward, 5′-CAC-
CATGGACTACAAGGACGACGATGACAAGACAGGAGTGTTTGACA-
GA-3′ and reverse, 5′-CTAATAGAGTGTCCCGGAGGC-3′; EGR3 forward, 
5′-CACCATGGACTACAAGGACGACGATGACAAGACCGGCAAACTC-
GCCGAG-3′ and reverse, 5′-TGAGGCGCAGGTGGTGACCAC-3′; ESR2 for-
ward, 5′-CACCACCATGGACTACAAGGACGACGATGACAAGGATATA-
AAAAACTCACCA-3′ and reverse, 5′-CTACTGAGACTGTGGGTTCTG-3′. 
The accuracy of cloned vectors was confirmed by DNA sequencing. The len-
tiviral shRNA for DLX5 (TRCN0000007448 and TRCN0000007449), EGR3 
(TRCN0000013843 and TRCN0000013847), and ESR2 (TRCN0000003325 
and TRCN0000003328) was purchased from Openbiosystems.
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